The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Innovent Biologics
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Asana BioSciences (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Celgene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Formation Biologics (Inst); Forty Seven (Inst); Genmab (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Incyte (Inst); Inhibrx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.
 
Neil Howard Segal
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Novartis; Numab; PureTech; Revitope
Research Funding - Agenus (Inst); AstraZeneca; Bristol-Myers Squibb; Immunocore; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Regeneron
 
Eugenia Girda
Consulting or Advisory Role - Merck
 
Davendra Sohal
Honoraria - Foundation Medicine
Consulting or Advisory Role - AADi; Ability Pharma; AstraZeneca/MedImmune; Bayer; Elevar Therapeutics; Totus Medicines; TransThera Sciences (Nanjing), Inc.; Valar Labs
Speakers' Bureau - AstraZeneca; Genentech; Incyte; Seagen
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); NextCure (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Triumvira Immunologics, Inc (Inst)
Travel, Accommodations, Expenses - Ability Pharma
 
Nehal J. Lakhani
No Relationships to Disclose
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Instil Bio; Merck; Nektar; Novartis; Pfizer; Takeda
Research Funding - Alkermes (Inst); Antengene (Inst); Eutilex (Inst); F-Star Biotechnology (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Intensity Therapeutics (Inst); Kadmon (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Sumitomo Group (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma
Consulting or Advisory Role - Actym Therapeutics; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; EMD Serono; ImmunoGenesis; Innovent Biologics; Janssen Oncology; Merck; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Hyunsil Han
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Kerry A. Casey
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Siyu Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Samit Ganguly
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Frank A. Seebach
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Melissa Divya Mathias
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)